Compare TPCS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | VERU |
|---|---|---|
| Founded | 1956 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 39.8M |
| IPO Year | N/A | 1990 |
| Metric | TPCS | VERU |
|---|---|---|
| Price | $4.49 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 53.3K | ★ 130.1K |
| Earning Date | 11-13-2025 | 12-16-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,564,000.00 | $16,886,419.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.15 | ★ 337.24 |
| 52 Week Low | $2.05 | $2.11 |
| 52 Week High | $6.25 | $14.20 |
| Indicator | TPCS | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 38.72 |
| Support Level | $4.41 | $2.11 |
| Resistance Level | $4.70 | $2.51 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 39.33 | 42.67 |
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.